Monday, October 14, 2013
A new report from
PricewaterhouseCoopers and the National Venture Capital Association shows the
number of companies receiving first-time venture investments has fallen to lows
not seen in nearly two decades.
The data compiled by PwC and
NVCA on venture investing do not paint a pretty picture. By their count, only
55 life science companies, including just 22 biotechs, received first-time VC
dollars in 1H13 - the lowest number since 1995.